Advancements in genetic analysis: Insights from a case study and review of next-generation sequencing techniques for veterinary oncology applications.
Journal
Veterinary clinical pathology
ISSN: 1939-165X
Titre abrégé: Vet Clin Pathol
Pays: United States
ID NLM: 9880575
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
revised:
03
08
2024
received:
14
04
2024
accepted:
22
08
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
5
10
2024
Statut:
aheadofprint
Résumé
Acute myeloid leukemia (AML) poses significant challenges in veterinary medicine, with limited treatment options and poor survival rates. While substantial progress has been made in characterizing human AML, translating these advancements to veterinary practice has been hindered by limited molecular understanding and diagnostic tools. The case study presented illustrates the application of whole genome sequencing in diagnosing AML in a dog, showcasing its potential in veterinary oncology. Our approach facilitated comprehensive genomic analysis, identifying mutations in genes that may be associated with AML pathogenesis in dogs, such as KRAS, IKZF1, and RUNX1. However, without supportive evidence of its clinical utility (eg, association with response to treatment or prognosis), the information is limited to exploration. This article reviews the comparative features of canine AML with human AML and discusses strategies to shrink the knowledge gap between human and veterinary medicine with cost-effective next-generation sequencing (NGS) techniques. By utilizing these approaches, the unique and shared molecular features with human AML can be identified, aiding in molecular classification and therapeutic development for both species. Despite the promise of NGS, challenges exist in implementing it into routine veterinary diagnostics. Cost considerations, turnaround times, and the need for robust bioinformatics pipelines and quality control measures must be addressed. Most importantly, analytical and clinical validation processes are essential to ensure the reliability and clinical utility of NGS-based assays. Overall, integrating NGS technologies into veterinary oncology holds great potential for advancing our understanding of AML and improving disease stratification, in hopes of improving clinical outcomes.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Veterinary Clinical Pathology published by Wiley Periodicals LLC on behalf of American Society for Veterinary Clinical Pathology.
Références
Cancer Statistics Review, 1975. SEER Statistics. 2018. Accessed November 4, 2021. https://seer.cancer.gov/csr/1975_2018/.
De Kouchkovsky I, Abdul‐Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. doi:10.1038/bcj.2016.50
Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481‐3485. doi:10.1182/BLOOD-2005-09-3724
Juliusson G, Antunovic P, Derolf Å, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood. 2009;113(18):4179‐4187. doi:10.1182/BLOOD-2008-07-172007
Harris RA, Rout ED, Yoshimoto JA, Avery PR, Avery AC. Using digital RNA counting to establish flow cytometry diagnostic criteria for subtypes of CD34+ canine acute leukaemia. Vet Comp Oncol. 2022;20(3):710‐719. doi:10.1111/VCO.12825
Stokol T, Nickerson GA, Shuman M, Belcher N. Dogs with acute myeloid leukemia have clonal rearrangements in T and B cell receptors. Front Vet Sci. 2017;4. doi:10.3389/fvets.2017.00076
Babraham Bioinformatics. FastQC A Quality Control Tool for High Throughput Sequence Data. Accessed September 9, 2022. https://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
Kinsella RJ, Kähäri A, Haider S, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford). 2011;2011. doi:10.1093/DATABASE/BAR030
Babraham Bioinformatics. Trim Galore. ! Accessed October 6, 2022. https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/.
Li H, Durbin R. Fast and accurate short read alignment with burrows‐wheeler transform. Bioinformatics. 2009;25(14):1754‐1760. doi:10.1093/BIOINFORMATICS/BTP324
Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43(1110):11.10.1–11.10.33. doi:10.1002/0471250953.BI1110S43
McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17(1):122. doi:10.1186/s13059-016-0974-4
Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747‐1756. doi:10.1101/GR.239244.118
Gerritsen M, Yi G, Tijchon E, et al. RUNX1 mutations enhance self‐renewal and block granulocytic differentiation in human in vitro models and primary AMLs. Blood Adv. 2019;3(3):320‐332. doi:10.1182/BLOODADVANCES.2018024422
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703‐1719. doi:10.1038/S41375-022-01613-1
Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526‐531. doi:10.1038/s41586-018-0623-z
Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059‐2074. doi:10.1056/NEJMOA1301689
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209‐2221. doi:10.1056/NEJMOA1516192
Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. Undefined. 2009;361(11):1058‐1066. doi:10.1056/NEJMOA0903840
Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol. 2013;97(2):165‐174. doi:10.1007/S12185-013-1257-4
Mroźek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515‐4523. doi:10.1200/JCO.2012.43.4738
Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453‐474. doi:10.1182/BLOOD-2009-07-235358
Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the beat AML master trial. Nat Med. 2020;26(12):1852‐1858. doi:10.1038/S41591-020-1089-8
Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39(11):1223‐1233. doi:10.1200/JCO.20.01659
Estey E, Hasserjian RP, Döhner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022;139(3):323‐332. doi:10.1182/BLOOD.2021011304
Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014;99(5):821. doi:10.3324/HAEMATOL.2013.096420
Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549‐1556. doi:10.1038/S41591-020-1008-Z
Kwok B, Hall JM, Witte JS, et al. MDS‐associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355‐2361. doi:10.1182/BLOOD-2015-08-667063
Li M, Binder M, Lasho T, et al. Clinical, molecular, and prognostic comparisons between CCUS and lower‐risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021;5(8):2272‐2278. doi:10.1182/BLOODADVANCES.2020003976
Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264‐278. doi:10.1016/J.CELL.2012.06.023
Bochtler T, Stolzel F, Heilig CE, et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol. 2013;31(31):3898‐3905. doi:10.1200/JCO.2013.50.7921
Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high‐throughput single‐cell genomics. Nat Commun. 2020;11(1):5327. doi:10.1038/S41467-020-19119-8
Usher SG, Radford AD, Villiers EJ, Blackwood L. RAS, FLT3, and C‐KIT mutations in immunophenotyped canine leukemias. Exp Hematol. 2009;37:65‐77. doi:10.1016/j.exphem.2008.09.005
Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348‐2357. doi:10.1182/BLOOD-2009-11-255976
Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23(24):4255‐4262. doi:10.1038/SJ.ONC.1207727
Davis LL, Hume KR, Stokol T. A retrospective review of acute myeloid leukaemia in 35 dogs diagnosed by a combination of morphologic findings, flow cytometric immunophenotyping and cytochemical staining results (2007–2015). Vet Comp Oncol. 2018;16(2):268‐275. doi:10.1111/VCO.12377
Jain NC, Blue JT, Grindem CB, et al. Proposed criteria for classification of acute myeloid leukemia in dogs and cats. Vet Clin Pathol. 1991;20(3):63‐82. doi:10.1111/J.1939-165X.1991.TB00571.X
Novacco M, Comazzi S, Marconato L, et al. Prognostic factors in canine acute leukaemias: a retrospective study. Vet Comp Oncol. 2016;14:409‐416. doi:10.1111/vco.12136
Bronzini I, Aresu L, Paganin M, et al. DNA methylation and targeted sequencing of methyltransferases family genes in canine acute myeloid leukaemia, modelling human myeloid leukaemia. Vet Comp Oncol. 2017;15:910‐918. doi:10.1111/vco.12231
Burnett RC, Vernau W, Modiano JF, Olver CS, Moore PF, Avery AC. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol. 2003;40(1):32‐41. doi:10.1354/VP.40-1-32
Mochizuki H, Shapiro SG, Breen M. Detection of BRAF mutation in urine DNA as a molecular diagnostic for canine urothelial and prostatic carcinoma. PLoS One. 2015;10(12):e0144170. doi:10.1371/JOURNAL.PONE.0144170
Brocks BAW, Bertram CA, Bartel A, et al. Internal tandem duplication of exon 8 of c‐kit is associated with longer Total survival in canine cutaneous mast cell tumors. Vet Pathol. 2021;58(2):315‐324. doi:10.1177/0300985820973463
London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto‐oncogene c‐kit. Exp Hematol. 1999;27(4):689‐697. doi:10.1016/S0301-472X(98)00075-7
Hédan B, Rault M, Abadie J, et al. PTPN11 mutations in canine and human disseminated histiocytic sarcoma. Int J Cancer. 2020;147(6):1657‐1665. doi:10.1002/IJC.32991
Alsaihati BA, Ho K‐L, Watson J, et al. Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. Nat Commun. 2021;12(1):4670. doi:10.1038/S41467-021-24836-9
Das S, Idate R, Lana SE, Regan DP, Duval DL. Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions. Sci Rep. 2023;13(1):10422. doi:10.1038/S41598-023-37266-Y
Hedan B, Thomas R, Motsinger‐Reif A, et al. Molecular cytogenetic characterization of canine histiocytic sarcoma: a spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer. 2011;11:201. doi:10.1186/1471-2407-11-201
Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next‐generation sequencing technologies. Nat Rev Genet. 2016;17(6):333‐351. doi:10.1038/nrg.2016.49
Satam H, Joshi K, Mangrolia U, et al. Next‐generation sequencing technology: current trends and advancements. Biology (Basel). 2023;12(7):997. doi:10.3390/BIOLOGY12070997
Sala‐Torra O, Reddy S, Hung L‐H, et al. Rapid detection of myeloid neoplasm fusions using single‐molecule long‐read sequencing. PLOS Glob Public Heal. 2023;3(9):e0002267. doi:10.1371/JOURNAL.PGPH.0002267
Wang J, Bhakta N, Ayer Miller V, et al. Acute leukemia classification using transcriptional profiles from low‐cost nanopore mRNA sequencing. JCO precis. Oncologia. 2022;6(6). doi:10.1200/PO.21.00326
Degner JF, Marioni JC, Pai AA, et al. Effect of read‐mapping biases on detecting allele‐specific expression from RNA‐sequencing data. Bioinformatics. 2009;25(24):3207‐3212. doi:10.1093/BIOINFORMATICS/BTP579
Peymani F, Farzeen A, Prokisch H. RNA sequencing role and application in clinical diagnostic. Pediatr Investig. 2022;6(1):29‐35. doi:10.1002/PED4.12314
Byron SA, Van Keuren‐Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016;17(5):257‐271. doi:10.1038/nrg.2016.10
Han Y, Gao S, Muegge K, Zhang W, Zhou B. Advanced applications of RNA sequencing and challenges. Bioinform Biol Insights. 2015;9(Suppl 1):29‐BBI.S28946. doi:10.4137/BBI.S28991
Marino P, Touzani R, Perrier L, et al. Cost of cancer diagnosis using next‐generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet. 2018;26(3):314‐323. doi:10.1038/s41431-017-0081-3
Sikkema‐Raddatz B, Johansson LF, de Boer EN, et al. Targeted next‐generation sequencing can replace sanger sequencing in clinical diagnostics. Hum Mutat. 2013;34(7):1035‐1042. doi:10.1002/HUMU.22332
Ip BBK, Wong ATC, Law JHY, et al. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. Sci Rep. 2024;14(1):1‐12. doi:10.1038/s41598-024-57016-y
Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4‐23. doi:10.1016/J.JMOLDX.2016.10.002
ICDC. Accessed April 11, 2024. https://caninecommons.cancer.gov/#/.
London CA, Gardner H, Zhao S, et al. Leading the pack: best practices in comparative canine cancer genomics to inform human oncology. Vet Comp Oncol. 2023;21(4):565‐577. doi:10.1111/VCO.12935
Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next‐generation sequencing‐based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American pathologists. J Mol Diagn. 2017;19(3):341‐365. doi:10.1016/J.JMOLDX.2017.01.011
Abraham R. Comparison of Next‐Generation Sequencing Techniques. https://app.biorender.com/biorender‐templates/figures/all/t‐61769d43516f2200a7e2d064‐comparison‐of‐next‐generation‐sequencing‐techniques.
Created in BioRender. Harris, A. (2024) BioRender.com/t38d237.
Created in BioRender. Harris, A. (2022) BioRender.com/q18u930.